You are not logged in and only seeing 7 days of articles. Please sign up or login to view more
Wednesday 31 July 2019

Sensyne Health signs milestone agreement with Bayer

Sensyne logoBritish clinical AI tech company Sensyne Health has signed a collaboration agreement with Bayer - its first major drug development agreement since IPO.  The initial two-year agreement, worth £5m to Sensyne, will see the AIM-listed start-up work with Bayer to accelerate the clinical development of new treatments for cardiovascular disease using its clinical AI technology platform. The collaboration with Bayer is a significant milestone for Sensyne Health that will underpin its growth over the next couple of years and has potential for further expansion. 

Oxford-based Sensyne IPO’d last August (see Sensyne raises £60m through IPO) and is in scale-up mode - in its first six months as a public company it made an operating loss of £5.1m on revenues of £39k. It is not your usual scale-up, however, and is definitely ‘one to watch’ in UK healthcare.  More...

Posted by: Tola Sargeant

Tags: startup   health   AI   scaleup  

Twitter   Facebook   LinkedIn   Email article link

© TechMarketView LLP 2007-2020: Unauthorised reproduction prohibited see full Terms and Conditions.